SEC Form 3 · accession 0001640334-19-000198
Inmune Bio, Inc. · INMB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Joseph Tesi
Officer — President & CEO · Director · 10% Owner
Period of report
Feb 1, 2019
Accepted (ET)
Feb 8, 2019 · 4:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001711754
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,515,833 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $7.80 | holding | — | — | — | — | Jan 28, 2028 | Common Stock | 400,000 | — | D |
Explanation of responses
- F1Of this amount options to purchase 277,778 shares of common stock are currently vested and the remaining options vest at the rate of 11,111 shares a month.